Halozyme Therapeutics Inc (NASDAQ:HALO)

Delayed Data
As of Mar 24
 +0.82 / +2.43%
Today’s Change
Today|||52-Week Range

Stock Price Forecast

The 9 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 52.00, with a high estimate of 68.00 and a low estimate of 26.00. The median estimate represents a +50.72% increase from the last price of 34.50.

Analyst Recommendations

The current consensus among 10 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past
months for detail


Earnings and Sales Forecasts

Current Quarter

Earnings per Share
Reporting Date
May 09

Earnings per Share

Move your mouse over a quarter or year to see how estimates have changed over time.

Growthquarterly -9.86%
Growthannually 44.18%


Growthquarterly -0.63%
Growthannually 26.35%
Key to the earnings and sales forecast charts.